HER-2-targeted therapy: lessons learned and future directions.
about
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapyDesign, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domainQuercetin-induced ubiquitination and down-regulation of Her-2/neuClinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells.HER2 expression as a potential marker for response to therapy targeted to the EGFR.Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.A current review of targeted therapeutics for ovarian cancer.Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.A conformationally constrained peptidomimetic binds to the extracellular region of HER2 proteinTargeted inhibition of kinases in cancer therapyStructure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines.A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer.Adjuvant trastuzumab: progress, controversies, and the steps ahead.Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity.Emerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy.Evaluation of immunohistochemistry and enzyme linked immunosorbent assay for HER-2/neu expression in breast carcinomaInvestigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples.Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients.HER-2-mediated endocytosis of magnetic nanospheres and the implications in cell targeting and particle magnetization.Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer.Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancerFluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore.Nanoradiopharmaceuticals for breast cancer imaging: development, characterization, and imaging in inducted animals.Lapatinib - overview and current role in metastatic breast cancerImaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistanceThe role of antioxidants in the era of cardio‑oncology.Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3.Biomarkers for rheumatoid arthritis: making it personal.New tools for classification and monitoring of autoimmune diseasesDownregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration.Trastuzumab- and Fab' fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo.Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant).
P2860
Q21198871-794CE0F3-CA26-457F-B552-2655B6D4889DQ24293331-0E6713CC-C963-4869-9953-BB9492606BB9Q24646978-A7D2F37B-431A-4244-BDD0-492AD4A289ABQ24810552-762D7FF0-5738-41F0-BE81-8F43676F8A96Q25255636-0045BD15-7C7F-47E0-BDE8-3B7F3C95D080Q33240248-C2C9F9A3-AF3F-4A22-9166-20DB11183B10Q33284158-349019A7-A0CB-412B-9193-F72261C176BAQ33580998-39DF34F3-ADED-45A1-B5F7-50641FAD0D0BQ33835904-F814769F-3F21-4D48-BFDF-D8D3729C0A90Q34103963-22CE8B73-F138-4723-A373-213D6FB5C752Q34422576-44BF353D-BEA9-494F-B81F-1496140AD7A8Q34683348-9CFE0C75-F788-4720-8544-F886C6A01305Q35185574-804E09ED-D874-4D87-B6BB-9BD5DC1555E0Q35678429-DAA7948B-8289-46A6-A8F0-E12579CDC828Q35840342-B3A4F7F6-5537-47DD-8910-B0A19786CB7AQ36101371-B9B2CDD8-1AAD-4FFB-8D32-5E4A9AE4BF37Q36111593-972233F1-7A98-40E2-BDFF-9346D06BAB87Q36263237-B82EB8AE-B3C2-4B59-8C9F-8DBE0563B750Q36439978-8607CE55-2DAB-4831-A682-1CF8A530C64EQ36465260-A923C9A5-E60B-416C-807D-4760799F9D72Q36559225-88693B98-4143-4BE3-9C21-43A82B502A81Q36610755-2389E5C4-5BC7-4FDF-B2C8-ED191E8B4878Q36642955-2C2C52E9-5781-4FA5-9A49-5A57E4D45043Q36745487-8118C567-C956-4651-ABF5-2F7D5BB9AF43Q37269743-E88646A5-C1B4-437C-A0C0-2D64754136C2Q37301332-6A6755A8-9AF2-4139-869A-8F567D4400A7Q37341649-AB05EBF6-E97E-48D7-B7BC-77A0E4E48956Q37558869-DB1B9BFA-8991-485D-8E9E-89710B952A10Q37626273-D26C9C84-3BC9-4ABA-AA99-A446C1AEBC00Q37721805-B4F9F122-7CB7-4859-992C-585795788B40Q37761911-BF33C16C-E538-4708-8573-0A3BF93204E3Q38014654-B032646E-9A69-4F6C-A973-E403FD08D19CQ40005854-A79C47AF-A271-48B8-BA46-A11BBFB1AF59Q47134924-30EB31D4-D210-49EB-88ED-1C45F1FB429AQ52614694-D7AB6D08-29BB-4C5E-8BF7-9B7F352FFBB0Q55403230-4FCCF67E-AE76-4228-BA4A-0C683EDD1C9A
P2860
HER-2-targeted therapy: lessons learned and future directions.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
HER-2-targeted therapy: lessons learned and future directions.
@ast
HER-2-targeted therapy: lessons learned and future directions.
@en
HER-2-targeted therapy: lessons learned and future directions.
@nl
type
label
HER-2-targeted therapy: lessons learned and future directions.
@ast
HER-2-targeted therapy: lessons learned and future directions.
@en
HER-2-targeted therapy: lessons learned and future directions.
@nl
prefLabel
HER-2-targeted therapy: lessons learned and future directions.
@ast
HER-2-targeted therapy: lessons learned and future directions.
@en
HER-2-targeted therapy: lessons learned and future directions.
@nl
P1476
HER-2-targeted therapy: lessons learned and future directions
@en
P2093
Rita Nahta
P304
P407
P577
2003-11-01T00:00:00Z